{
    "2018-07-03": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Adamis (ADMP) Surges Following Novartis Deal for Symjepi",
                "features": {
                    "keywords": [
                        "Adamis",
                        "Novartis",
                        "Deal",
                        "Symjepi",
                        "Surges"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-29",
                "original_text": "GlaxoSmithKlineâ€™s Valuation on June 29",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "Valuation"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "The Swiss Stock Markets Climbed On Strength Of Defensive Heavyweights",
                "features": {
                    "keywords": [
                        "Swiss Stock Markets",
                        "Climbed",
                        "Defensive Heavyweights"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "defensive sectors"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Adamis has a partner to market its EpiPen competitor after a year-long search",
                "features": {
                    "keywords": [
                        "Adamis",
                        "EpiPen",
                        "competitor",
                        "partner",
                        "year-long search"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}